In DepthPUBLIC HEALTH

First opioid settlement lets researchers think big

See allHide authors and affiliations

Science  05 Apr 2019:
Vol. 364, Issue 6435, pp. 11-12
DOI: 10.1126/science.364.6435.11

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

A fledgling, small-scale approach to dealing with the state's opioid crisis paid off big last week for Oklahoma State University (OSU) when it became the surprise beneficiary of a $270 million legal settlement with Purdue Pharma. It's the first agreement in some 1700 pending cases around the United States against Purdue, which makes the painkiller OxyContin, and other manufacturers of prescription opioids. On 26 March the state of Oklahoma agreed to drop its suit alleging deceptive marketing practices by Purdue in exchange for a National Center for Addiction Studies and Treatment at OSU's medical complex in Tulsa. Purdue and the Sackler family, which owns the Stamford, Connecticut–based company, will provide a $177 million endowment for the national center, along with $20 million over 5 years for naloxone and other drugs to treat opioid addiction. The state is continuing its suit against several other companies, with opening arguments set for 28 May.

View Full Text

Stay Connected to Science